Grants for Public and State controlled institutions of higher education - Federal

U.S. Embassy Riyadh announces an open competition for organizations to submit applications to carry out a program that provides exchange opportunities for emerging Saudi leaders in video game development and fosters linkages between them and experienced U.S. practitioners, professionals, educators and peers. Please read this document carefully and follow all instructions. This notice is subject to availability of funding.

The U.S. Department of State, Bureau of Democracy, Human Rights, and Labor (DRL) announces an open competition for organizations interested in eradicating descent-based slavery and discrimination towards enslaved and formerly enslaved persons in the Sahel region of West Africa. Two projects will be awarded; one for Mauritania only and one regional project, focused on two or more countries in the Sahel region of West Africa. If applying to both opportunities, applicants should submit two separate applications.

Substance use needs to be better incorporated into interventions for the engagement and retention of sexual minority persons in prevention and care with attention to emergent interventions such as long-acting PrEP. Social determinants of health associated with HIV and problematic substance use such as homelessness and criminal justice involvement also demonstrate disproportionate impact among sexual and gender minorities and need attention. Changing self-definition of sexual minority status has implications for outreach and provider stigma and needs to be better integrated into interventions. This initiative will address these gap areas and support epidemiologic, intervention, and implementation research that incorporates attention to HIV as a syndemic including comorbidities such as STIs, HCV, and psychiatric disorder.

This funding opportunity supports research projects that improve agricultural sustainability and productivity by integrating genetics, environmental data, and advanced analytics, targeting universities, research institutions, and private organizations.

This funding opportunity provides financial support to a variety of organizations, including local governments and nonprofits, to strengthen the capacity of regional authorities in Tanzania to effectively manage and deliver comprehensive HIV and tuberculosis prevention, care, and treatment services.

This funding opportunity supports researchers in analyzing and integrating existing data to better understand cancer risks and outcomes, ultimately advancing cancer research and treatment strategies.

This funding opportunity provides financial support for alumni of U.S. government-sponsored exchange programs in North Macedonia to implement innovative public service projects that address local and global challenges.

This funding opportunity invites businesses, universities, and nonprofit research organizations to develop innovative technologies in advanced electronics, sensors, and electronic warfare to support U.S. Navy national security objectives.

The United States Department of the Interior (Department), Bureau of Reclamations (Reclamation) Desalination and Water Purification Research Program (DWPR) works with Reclamation researchers and partners to develop innovative, cost-effective, and technologically efficient ways to desalinate and treat water. DWPR funding plays a critical role in iterating an idea from the lab to a real-world demonstration, yielding products that serve the water treatment community and attract commercialization interest. Reclamation is interested in research where the benefits are widespread but where private-sector entities are not able to make the full investment and assume all the risks. Reclamation is also interested in research that has a national significancewhere the issues are of large-scale concern and the benefits accrue to a large sector of the public. The goal of the DWPR program is to address the need to reduce the costs, energy requirements, and environmental impacts of treating impaired and unusable water. The program also aligns with Executive Order 14008, Tackling the Climate Crisis at Home and Abroad, by investing in development and application of advanced water treatment technologies that expand access to otherwise unusable water resources, thereby increasing water supply flexibility under the risks of long-term climate change and shorter-term drought. For further information on the DWPR Program, see www.usbr.gov/research/dwpr.

The National Cancer Institute intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications forresearch on the confluence of cancer stigma and HIV stigma in HIV-positive individuals diagnosed with cancer. This NOFO will utilize the R01 grant mechanism (clinical trial optional). Up to six (6) R01 awards are expected to be funded as part of the initiative. Research projects search project will advance the current understanding of the confluence of cancer stigma and HIV stigma among people with HIV (PWH) diagnosed with cancer; assess the impact of these two converging stigmas on cancer outcomes among PWH with cancer; leverage stigma reduction interventions at multiple levels to intervene on modifiable mechanisms of stigma that contribute to negative cancer outcomes among PWH with cancer; and promote research in diverse domestic and international contexts, focusing on regions in which the HIV-cancer burden is elevated. The NOFO is expected to be published in late Summer 2024 with an expected application due date in late Fall 2024. Details of a pre-application webinar will be announced after the publication of the NOFO. This Notice is being provided to allow sufficient time for potential applicants with relevant expertise and insights to consider applying for this NOFO. Potential applicants are encouraged to view the presentation of this initiative to the Joint Virtual Meeting of the NCI Board of Scientific Advisors and the National Cancer Advisory Board available at https://videocast.nih.gov/watch=54859 beginning at 3 hour, 39 minutes. Presentation slides are downloadable at: https://deainfo.nci.nih.gov/advisory/joint/0624/Vanderpool.pdf.

This grant provides funding for a Data Coordinating Center to support research projects focused on preventing stillbirth, emphasizing collaboration and equity in addressing disparities in vulnerable populations.

The "Research on Autism Spectrum Disorders" grant aims to fund projects that explore the causes, prevalence, diagnosis, and best service delivery methods for Autism Spectrum Disorders, with a focus on small, well-defined projects that can be completed within two years using limited resources.

This funding opportunity provides financial support to schools and school districts to conduct a pilot study aimed at reducing harmful contaminants in meals served to students and improving their nutritional quality.

The National Institutes of Health (NIH) hereby notify recipient organizations holding specific types of NIH grants, listed in the full Funding Opportunity Announcement (FOA), that applications for change of recipient organization may be submitted to this FOA. This assumes such a change is programmatically permitted for the particular grant. Applications for change of recipient organization are considered prior approval requests (as described in Section 8.1.2.7 of the NIH Grants Policy Statement) and will be routed for consideration directly to the Grants Management Specialist named in the current award. Although requests for change of recipient organization may be submitted through this FOA, there is no guarantee that an award will be transferred to the new organization. All applicants are encouraged to discuss potential requests with the awarding IC before submission.

The purpose of this Notice of Funding Opportunity (NOFO) is to support the development of clinical research platforms that will enable future clinical trials to determine whether combinations of HIV cure strategies can be effective when optimally tailored to the participants. The ultimate goal is for the results of such proof-of-concept clinical studies to inform the development and prioritization of more broad-based curative strategies that will be effective in all people living with HIV. This NOFO will support multidisciplinary teams to conduct coordinated basic and pre-clinical research to profile participants intact, rebound-competent HIV reservoirs and immunologic backgrounds and use that information to develop and test combinations of HIV curative approaches that are specifically tailored to those participants.

Modified release (MR) oral drug products are considered to have a high risk for alcohol dose dumping (ADD) because they contain large quantities of drug(s), designed to release over a prolonged period of time. Accidental exposure of these products to alcohol can result in the relatively rapid release of large quantities of drug with severe side effects, including death. To mitigate this risk, the FDA recommends conducting an in vitro alcohol dose dumping assessment in 0%, 5%, 20%, and 40% alcoholic dissolution media for all prospective generic versions of MR oral drug products. To date, ADD assessments have not been harmonized globally. For instance, the U.S. FDA recommends testing up to 40% alcoholic media while the European Medicines Agency recommends testing up to 20% alcoholic media. This type of difference can present a challenge for formulators designing products for multiple markets, as historical data has shown release from MR oral products do not always follow a linear response (either increasing or decreasing) to increasing alcohol concentrations. In addition, interpretation of an ADD assessment may be limited by the inability of the test to predict in vivo behavior. The purpose of this research is to develop tools that 1) facilitate the development of MR generic drug products that have a low potential for ADD, 2) support regulatory decision making during the assessment of such products, and 3) provide evidence that enables FDA to develop more specific recommendations for efficiently demonstrating a low or comparative potential of alcohol dose dumping for MR oral drug products containing high risk drugs.

The FY24 DMDRP IDA promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with DMD. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale.New Investigators: The FY24 DMDRP IDA mechanism encourages applications from independent investigators in the early stages of their careers (i.e., within 10 years of their first faculty appointment or equivalent) or applications from established investigators new to DMD research.The New Investigator Early Stage category is designed to allow applicants early in their faculty appointments to compete for funding separately from established investigators.The New Investigator Transitioning category is designed to allow investigators in an area other than muscular dystrophy, at or above the level of Assistant Professor, seeking to transition to a career in DMD, thereby bringing their expertise to the field.Applications from New Investigators and Established Investigators will be peer and programmatically reviewed separately. Principal Investigators (PIs) using the New Investigator Early Stage category or New Investigator Transitioning category are strongly encouraged to strengthen their applications by collaborating with investigators experienced in DMD research and/or possessing other relevant expertise. It is the responsibility of the applicant to describe how the included collaboration will augment the PIs expertise to best address the research question. All applicants for the New Investigator categories must meet the specific eligibility criteria described in Section II.C, Eligibility Information.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required. Preliminary data may include unpublished results from the laboratory of the PI, research team or collaborators named on the application.Key elements of this award are as follows:Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities.Impact: Research that has high potential impact may lead to major advancements and significantly accelerate progress toward improving outcomes for individuals with DMD.It is the responsibility of the PI to clearly and explicitly articulate the projects innovation and its potential impact on DMD. The projects impact to both DMD research and to individuals with DMD should be articulated, even if clinical impact is not an immediate outcome. Applications that demonstrate exceptional scientific merit but lack innovation and high potential impact do not meet the intent of the IDA.Clinical trials are not allowed under this funding opportunity.A clinical trial is defined in 45 CFR 46.102 as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.

This funding opportunity supports organizations that empower women in El Salvador by providing professional development programs to enhance their business skills and promote economic growth.

This funding opportunity supports small-scale brain imaging research related to substance use and addiction, aimed at helping both new and established researchers develop innovative studies that enhance our understanding of neurobiological mechanisms in these areas.

This grant provides funding for academic training programs to develop skilled professionals in vocational rehabilitation, specifically targeting individuals who will support people with disabilities.